Life sciences veterans Mario Philips and Roel Gordijn have launched Enovo Life Sciences, partnering with Warburg Pincus, a prominent global growth investor. Enovo aims to identify and acquire companies to create a leading life sciences platform focused on biologics and advanced therapies. This initiative is supported by Warburg Pincus's $17.3 billion flagship fund, Warburg Pincus Global Growth 14.

Philips and Gordijn bring over 50 years of combined experience in the life sciences sector, particularly in vaccine and antibody manufacturing, as well as Advanced Therapy Medicinal Products. They previously played significant roles in Warburg Pincus's investment in Polyplus, which was sold for €2.4 billion to Sartorius Stedim Biotech last year.

Philips, the CEO of Enovo, emphasized the company's goal to acquire firms with proven capabilities and growth potential. He stated that Enovo will provide the necessary capital to foster innovation that meets customer and patient needs, leveraging Warburg Pincus's extensive global network. Gordijn expressed excitement about building Enovo and pursuing partnerships with businesses that have unique offerings and expertise across the U.S. and Europe.

T.J. Carella, Managing Director at Warburg Pincus, highlighted the firm's commitment to innovative life sciences products and services. He believes that biologics and advanced therapies hold significant potential for patient impact. Ruoxi Chen, another Managing Director at Warburg Pincus, praised Philips and Gordijn's track record in leading global life sciences businesses, deeming them ideal for launching this new platform.

Enovo will benefit from Warburg Pincus's teams in London, New York, and other global offices. This launch aligns with Warburg Pincus's broader strategy to strengthen its healthcare investment practice, recently underscored by the appointment of Jake Strauss to lead healthcare investments in Europe.

Warburg Pincus has a robust history in healthcare, having invested over $18 billion in more than 180 healthcare companies, including notable names like Summit Health and Bausch + Lomb. The firm, founded in 1966, manages over $83 billion in assets and has a diverse portfolio of over 225 companies across various sectors and geographies.